Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The designation "No conventional molecular drug target" is utilized in pharmacological classification to identify therapeutic agents whose primary mode of action does not involve binding to a specific protein, such as a receptor, enzyme, or ion channel (ChEMBL Database, 2024). These agents typically exert their effects through broad physical or chemical interactions within the physiological environment. For example, antacids like aluminum hydroxide work by directly neutralizing gastric hydrochloric acid to mitigate acidity (StatPearls, 2023). Osmotic laxatives and diuretics, such as polyethylene glycol and mannitol, function by altering osmotic pressure to facilitate fluid movement (PubChem, 2024). Additionally, adsorbents like activated charcoal provide a large surface area to physically trap toxins, preventing their systemic absorption (StatPearls, 2023). Because these substances lack a discrete molecular binding site, they are generally not subject to traditional structure-based drug design or target-validation studies.
Physical or chemical interactions including neutralization, osmosis, adsorption, and surface tension modification.
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on No conventional molecular drug target.